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eMethods 
Maximising specificity of genetic variants:  excluding single nucleotide polymorphisms (SNPs) with effects 
on multiple traits (“pleiotropic” SNPs) 
It was important to ensure that each genetic score would enable us, as far as possible, to capture specifically the 
respective maternal trait. To identify SNPs with pleiotropic effects, we queried each of our initial 193 selected 
SNPs and all SNPs in linkage disequilibrium with these (r2>0.2) using the National Human Genome Research 
Institute (NHGRI) catalog of published genome-wide association studies (GWAS)1 and listed SNPs associated 
with other traits at P < 5x10-8. Starting with this list, we excluded SNPs whose location near a candidate gene 
and/or the strength of association with another trait suggested that the association with the maternal exposure of 
interest is almost certainly secondary to the other trait (e.g. exclusion of index SNPs at FTO and MC4R from the 
type 2 diabetes genetic score, since these are primarily associated with BMI and secondarily with type 2 
diabetes via their effect on BMI). We additionally excluded SNPs from the list with strong evidence of effects 
on two or more traits that are potentially relevant to the maternal environment and birth weight. Details of SNPs 
in the final selected list are shown in eTable 3.  
 
We performed an updated search of the NHGRI catalog, while writing the research paper, to check for further 
pleiotropic associations identified for SNPs used in our analyses, which were published after our initial search. 
We performed sensitivity analyses excluding these additional SNPs to check that they did not alter our findings 
(results available from the authors on request). 
 
Maximising specificity of genetic variants: separating genetic scores for closely-related maternal traits 
Fasting glucose and type 2 diabetes share several genetic susceptibility variants, reflecting the overlap between 
these two phenotypes (eTable 3). We excluded from the type 2 diabetes genetic score the index SNPs at the two 
fasting glucose loci that explain the most variance in fasting glucose, but have relatively moderate effects on 
type 2 diabetes risk (MTNR1B and GCK). Likewise, we excluded the index SNP at the TCF7L2 locus from the 
fasting glucose genetic score as it has a proportionately much larger effect on type 2 diabetes risk. In this way, 
our fasting glucose genetic score would predominantly capture variation in maternal fasting glucose in the 
normal physiological range, while our type 2 diabetes genetic score would be more likely to capture 
pathologically-raised fasting and non-fasting maternal glucose levels.  
 
Maternal triglycerides and HDL-cholesterol also share associations with several genetic variants. We therefore 
attempted to make our genetic scores for these exposures as specific as possible. For HDL- cholesterol, we 
included only SNPs near genes associated with known Mendelian lipid disorders (see eTable 3)2. For 
triglyceride levels, SNPs were included in the genetic score if they were solely associated with triglyceride 
levels, or if their effect on triglyceride levels was at least three times greater than that of HDL-, LDL- or total 
cholesterol, based on effect sizes reported in 2. To facilitate these comparisons, the raw effect sizes in mg/dL 
were first converted to percentages of the mean of the corresponding lipid concentration.  
 
SNPs missing from studies 
When index SNPs were missing from individual studies, we used the SNP Annotation and Proxy Search tool, 
SNAP3 to identify suitable proxy SNPs (r2 > 0.8). If a study had fewer than 80% of the index or proxy SNPs 
required to generate a specific genetic score, it was excluded from the analysis. The one exception to this was 
the HAPO (non-GWAS) Study, for which only 6 of 17 triglyceride SNPs had been genotyped. We included this 
study, despite the missing SNPs, because the 6 genotyped SNPs included those with the largest effects on 
triglyceride levels, covering the majority of variation captured by the 17-SNP score.  
 
Imputation quality 
For each study with GWAS data, we examined the imputation quality (r2 4 or proper_info5) of SNPs selected for 
each score. We excluded four studies (B58C-WTCCC, NFBC1966, QIMR and TwinsUK) from analyses of the 
adiponectin genetic score due to imputation quality scores <0.8 for either 1 or 2 of the 3 SNPs in that score. In 
each of the remaining 7 genetic scores, a small number of included SNPs had imputation quality scores <0.8, 
but this only affected a median of 0 to 1 SNP per study, equivalent to a maximum of 6% of the SNPs 
comprising the score, so we did not exclude them. Finally, we identified that 3 individual SNPs were poorly 
imputed (r2<0.8) in multiple studies: rs10830963 (fasting glucose genetic score, 4 of 15 studies), rs11063069 
(type 2 diabetes genetic score; 11 of 13 studies) and rs13238203 (triglycerides genetic score; 11 of 16 studies). 
To verify that these individual SNPs did not materially alter our results, we performed sensitivity analyses: (i) 
we repeated the meta-analyses of the fasting glucose genetic score excluding the 4 studies in which SNP 
rs10830963 was poorly imputed; (ii) we performed weighted meta-analyses of existing summary GWAS data6, 
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as described previously7 both including and excluding the rs11063069 and rs13238203 SNPs. Results of these 
analyses are available from the authors on request. 
 
Calculation of maternal genetic scores 
We calculated a weighted genetic score for each maternal exposure to account for the fact that some SNPs have 
relatively larger effects than others.  Formula 1 below describes the calculation, where w is the weight and SNP 
is the number of trait-raising or lowering alleles at that locus. The decision to model according to the trait-
raising or lowering allele was informed by the known association between each maternal trait and BMI (Box 1). 
The weights used for each SNP were obtained from published GWAS of non-pregnant individuals, which either 
did not include any of the studies used in this paper or had at most 17% of participants overlapping. These 
weights and their sources, are summarised in eTable 3.   
 Weighted	score = w/×SNP/ + w5×SNP5 + ⋯w7×SNP7				(1)  
 
We rescaled each weighted genetic score (GS) to reflect the number of available SNPs using formula 2 as 
described in Lin et al 8 
 GS = Weighted	Score	x	Number	of	SNPs	availableSum	of	weights	of	available	SNPs 																					(2) 
 
Meta-analyses 
We meta-analysed data from all available studies to give an overall result from each side of the triangle (Figure 
1): the genetic score-maternal exposure association; the genetic score-birth weight association; and the 
observational maternal exposure-birth weight association. We combined the regression coefficients and standard 
errors from individual study analyses by performing inverse variance meta-analyses with fixed effects as there 
was little evidence of between-study heterogeneity of effect size. All meta-analyses were performed using the 
user-written Stata command, metan.9 We estimated the percentage of total variation among study estimates due 
to between-study heterogeneity using Cochran’s Q test and the I2 statistic.10 To convert the overall results from 
birth weight and ponderal index Z-scores into grams and kgm-3 respectively, we multiplied the effect size and 
their upper and lower 95% confidence limits by a representative value of the standard deviation of birth weight 
(484g)11 or ponderal index (2.78 kgm-3;  ALSPAC study).  
 
Mendelian randomization analysis 
We performed instrumental variable (IV) estimation using the ratio estimator 12. We estimated the effect of each 
maternal exposure on either birth weight or ponderal index by dividing the overall genetic score -birth weight or 
genetic score -ponderal index association by the overall genetic score -maternal exposure association. The 
standard error of these estimates was calculated using a Taylor series approximation 13: we used a 2nd order 
Taylor series expansion to obtain the variance of the IV estimate. We then made a normal distribution 
assumption by calculating the 95% confidence interval as follows: IV estimate -/+ 1.96*sqrt(variance of IV 
estimate from Taylor series expansion). 
 
We used a Z-test to test for a difference between the instrumental variable (genetic) and observational 
associations. The Z-score was calculated by estimating the covariance between the observational and 
instrumental variable (genetic) estimates using a bootstrapping procedure.	We used the following formula for 
our Z-test: 
 
Z = (difference between IV and observational estimate)/sqrt(variance of difference between the estimates) 
 
where the variance of the difference between the estimates is given by: 
var(IV estimate) + var(observational estimate) - 2*cov(IV estimate, obs estimate) 
 
The covariance between the IV and observational estimates was estimated by nonparametric bootstrapping the 
IV and observational estimates using 20 replications (we chose a relatively small number of replications because 
we included meta-analyses with up to 18 studies). We then compared the Z-statistic with a standard normal 
distribution. 
 
Guarding against weak instrument bias 
Mendelian randomization studies may be susceptible to weak instrument bias. Bias is the difference between the 
estimated value of a parameter and its true value. Weak instrument bias occurs in the direction of the 
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confounded observational association if the instrument (i.e. the genetic score) is only weakly associated with the 
phenotype (i.e. the maternal trait).14 The strength of each instrument used in our study is a function of (i) the 
proportion of variance in the maternal trait explained by the genetic score and (ii) the sample size. Since the 
variance in each maternal trait explained by the genetic score was modest, we maximized the sample size 
(Table 2). The possible causal associations identified in our study are therefore unlikely to be due to weak 
instrument bias. 
 
Control for population stratification 
The presence of subpopulations, which differ in mean birth weight and have genetic variants present at different 
frequencies, can cause artificial associations between genotypes and birth weight. To ensure that the genetic 
associations we tested were not confounded in this way, we took the following steps: (i) we included only 
women of European ancestry; (ii) where necessary, analyses in the individual studies were adjusted for ancestry 
principal components; (iii) in those studies that had performed a genome-wide association study of birth weight, 
we checked the genomic control lambda values (ratio of median of the empirically observed distribution of the 
test statistic to the expected median), which suggested only minimal inflation: median lambda = 1.006 [inter-
quartile range: 1.004-1.012]; (iv) we combined summary statistics from individual studies by inverse variance 
meta-analysis, thereby controlling for any population stratification between studies in the overall sample. 
Sensitivity analyses 
The ascertainment of offspring birth weight or gestational age data varied among the individual studies, from 
measurement by trained study personnel, to ascertainment from medical records or birth registries, to self-report. 
To verify that our results were unaffected by the varying quality or availability of phenotypic data, we 
performed sensitivity meta-analyses of the associations between the 8 genetic scores and birth weight in up to 12 
studies with best quality data (i.e. measured or medical record birth weight and gestational age available). 
Results of these analyses are available from the authors on request. 
To verify that the SBP genetic score-birth weight associations were unaffected by using weights from the 
original GWAS15 which were adjusted for BMI, we performed a blood pressure GWAS in 127,698 individuals 
of British descent using the UK Biobank data. The UK Biobank recruited over 500,000 individuals aged 37-73 
years (99.5% were between 40 and 69 years) in 2006-2010 from across the country16. Two blood pressure 
readings were taken approximately 5 minutes apart using an automated Omron blood pressure monitor. Two 
valid measurements were available for most participants, and the average was taken. Individuals were excluded 
if the two readings differed by more than 4.56SD, and blood pressure measurements more than 4.56SD away 
from the mean were excluded. We accounted for blood pressure medication use by adding 15 to the systolic 
blood pressure measure. Valid blood pressure measurements were available for 120,008 individuals. Blood 
pressure was adjusted for age, sex and centre location and then inverse normalized.The weights from the blood 
pressure GWAS in the UK Biobank were utilised to create a genetic risk score in the ALSPAC study (n=7,304). 
We investigated the correlation of the two blood pressure risk scores (r2=0.77) and performed Mendelian 
randomization. The results are available from the authors on request.   
Estimating how much of the possible causal effect of BMI on birth weight is mediated by fasting glucose 
To begin to understand what proportion of the estimated causal effect of BMI on birth weight might be mediated 
by fasting glucose, we first estimated the causal effect of BMI on maternal fasting glucose. Using available 
studies (see eTable 6a), each additional allele of the BMI genetic score was associated with a 0.145 kg/m2 
(95%CI: 0.126, 0.164) higher BMI and a 0.005 mmol/L (95%CI: 0.001, 0.009) higher fasting glucose. This is 
equivalent to 0.34 SD higher fasting glucose level per 1 SD higher genetically instrumented BMI. (To convert to 
SD units, we used BMI SD = 4 kg/m2 and fasting glucose SD = 0.4 mmol/l.) We then multiplied the genetic 
estimate and 95%CI for the effect of fasting glucose on birth weight (114g [95%CI: 80, 147g]) by 0.34 to 
represent the possible causal effect of fasting glucose on birth weight for every 1 SD higher maternal BMI.  
 
Since we found genetic evidence that systolic blood pressure (SBP) was causally associated with birth weight in 
the opposite direction and positively associated with BMI, we additionally estimated the causal effect of BMI on 
SBP. Each additional allele of the BMI genetic score was associated with a 0.07 mmHg (95%CI: 0.02, 0.11) 
higher SBP. This is equivalent to 0.19 SD higher SBP per 1 SD higher genetically instrumented BMI. (To 
convert to SD units, we used SBP SD = 10 mmHg.) We then multiplied the IV estimate and 95%CI for the 
effect of SBP on birth weight (-208g [95% CI: -394, -21]) by 0.19 to represent the causal effect of SBP on birth 
weight for every 1 SD higher maternal BMI.  
 
Power calculations 
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Using data available from the ALSPAC study, we estimated the variance explained in birth weight (BW) by 
each maternal genetic score as the difference in adjusted-R2 values between linear regression models (i) and (ii) 
as follows:  
(i) BW = sex + gestational_age 
(ii) BW = sex + gest_age + genetic_score 
We then used these values to estimate (a) the power available in our included sample to detect evidence of 
association between maternal genetic score and birth weight at P<0.05, and (b) the minimum sample size needed 
to detect association between maternal genetic score and birth weight at P<0.05 with 80% power. Power 
calculations were performed using Quanto v.1.2 (http://biostats.usc.edu/software). 
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eFigure 1. Comparison of the observational with the genetic change in ponderal index (in kg/m3) for a 1 standard deviation (SD) change in each maternal trait. For 25[OH]D and adiponectin, 
we present the change in ponderal index for a 10% change in maternal trait level because these variables were logged for analysis.  The genetic change was estimated from Mendelian 
randomization analysis, in which a genetic score was used to estimate the possible causal effect of the maternal trait on ponderal index. The genetic estimate is presented twice: in the second 
case it was adjusted for fetal genotype using a subset of the available studies. The error bars represent the 95% confidence intervals around the effect size estimates.  
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eFigure 2. Estimating how much of the estimated possible causal effect of maternal BMI on birth weight is mediated by maternal fasting glucose. The solid, horizontal arrow indicates our 
genetic estimate [95%CI] of the causal effect of BMI on birth weight. The dashed arrows on the left side show genetic causal estimates of a 1 SD (≈ 4kg/m2) higher maternal pre-pregnancy 
BMI on maternal fasting glucose (+0.34SD ≈ 0.14 mmol/L) and maternal systolic blood pressure in pregnancy (+0.19 SD ≈ 2 mmHg). The dashed arrows on the right show the scaled genetic 
causal estimates of these changes in fasting glucose and systolic blood pressure on birth weight. The effect of maternal BMI on birth weight via fasting glucose (+ 39g) is broadly similar to the 
total effect of maternal BMI on birth weight (+55g), but that effect is opposed by the birth weight lowering effect of SBP (-40g). Overall, this suggests that while maternal fasting glucose 
mediates part of the positive association between maternal BMI and birth weight, other BMI-related factors are likely to be involved. Abbreviations: BMI, body mass index; BW, birth weight; 
FPG, fasting plasma glucose; SBP, systolic blood pressure. 
 
 
BMI 
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FPG 
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8	
	
eTable 1(a) Basic characteristics of study participants and their offspring (studies 1-5) 
  
STUDY ALSPAC  Mothers Berlin Birth Cohort (BBC) Mothers 
1958 British Birth 
Cohort or NCDS 
(B58C-WTCCC) 
1958 British Birth 
Cohort or NCDS 
(B58C-T1DGC) 
CHOP Mothers 
STUDY 
INFORMATION 
Ethnicity British/European descent European descent British/European descent 
British/European 
descent European American 
Country (Sample 
source) UK Germany UK UK 
United States of 
America 
Collection type (e.g. 
population-based) Population-Based
 Community-based Population-based Population-based Population-based 
N women with birth 
weight of 1 child and 
genotypes for at least 
one genetic score 
7,304 1,357 855 836 312 
Year(s) of birth  of 
offspring April 1991 - Dec 1992 2000-2004 1972-2000 1972-2000 1987-present 
Fetal  genotype data 
available? (Y/N) Y Y N N Y 
BIRTH WEIGHT 
Method by which 
offspring birth weight 
(and length, if 
available) were 
collected 
Obstetric records / measured 
by trained study personnel   
Measured by trained 
personnel immediately 
after birth 
Maternal self-report 
(information from 
questionnaires at age 
33 and 42 years) 
Maternal self-report 
(information from 
questionnaires at age 
33 and 42 years) 
Questionnaire and 
EPIC medical 
records (9.5% of 
questionnaire values 
were checked against 
medical records: 
r=0.83). 
GESTATIONAL AGE 
Method by which 
gestational age was 
collected 
By date of last menstrual 
period (LMP), paediatric 
assessment, obstetric 
assessment, ultrasound 
assessment.  
Calculated from LMP 
and corrected by 
ultrasound, if the 
difference was > 2 
weeks 
From maternal self-
report at ages 33 and 
42 years: a question 
inquiring if the child 
was born at term, or 
alternatively how 
many weeks in 
advance or late.  
From maternal self-
report at ages 33 and 
42 years: a question 
inquiring if the child 
was born at term, or 
alternatively how 
many weeks in 
advance or late.  
NA 
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 ALSPAC  Mothers Berlin Birth Cohort (BBC) Mothers 
1958 British Birth 
Cohort or NCDS 
(B58C-WTCCC) 
1958 British Birth 
Cohort or NCDS 
(B58C-T1DGC) 
CHOP Mothers 
SUMMARY 
MATERNAL 
CHARACTERISTICS, 
where available in the 
INCLUDED sample, 
DURING 
PREGNANCY 
(median (IQR) given 
where the trait 
distribution deviates 
strongly from the 
normal distribution 
Maternal age at 
delivery, unless 
otherwise stated [Mean 
(sd)], years  
28.5 (4.8) 30.1 (5.4) 26.2 (5.2) 26.1 (5.4) NA 
Maternal pre-
pregnancy BMI [Mean 
(sd)], kg/m2  
22.93 (3.73) 22.78 (3.93) NA NA NA 
Maternal pregnancy 
BMI [Mean (sd)], 
kg/m2 
26.63 (4.03) 28.39 (4.25) NA NA NA 
Fasting glucose [Mean 
(sd)], mmol/L NA NA NA NA NA 
Triglycerides [Mean 
(sd)], mmol/L   NA NA NA NA NA 
HDL-cholesterol 
[Mean (sd)], mmol/L NA NA NA NA NA 
Blood pressure [Mean 
(sd)], mmHg 112.9 (7.5)/65.5 (4.8) 
117.28 (10.85)/70.73 
(7.56) This was 
measured at the 3rd 
trimester. 
NA NA NA 
25-hydroxyvitamin D 
[Median (IQR)], 
nmol/L   
62.1 (43.6, 85.4) NA NA NA NA 
Adiponectin [Mean 
(sd)], ug/mL NA NA NA NA NA 
N (%) of mothers who 
smoked in pregnancy 1,278 (17.5%) 212 (15.6%) 325 (38.0%) 285 (34.1%) NA 
Mean gestational week 
of  collection of 
maternal 
characteristics 
28 28 Retrospective Retrospective NA 
N (%) Parity ( 
primiparous births) 2,483 (34%) 727 (53.6%) 855 (100%) 836 (100%) NA 
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 ALSPAC  Mothers Berlin Birth Cohort (BBC) Mothers 
1958 British Birth 
Cohort or NCDS 
(B58C-WTCCC) 
1958 British Birth 
Cohort or NCDS 
(B58C-T1DGC) 
CHOP Mothers 
SUMMARY  
OFFSPRING 
CHARACTERISTICS 
(offspring of the 
INCLUDED sample of 
mothers) 
Birth weight [Mean 
(sd) ], grams 3481 (475) 3472 (511) 3325 (483) 3379 (469) 3440 (562) 
Gestational age at 
delivery [Median 
(IQR)], weeks 
40 (39, 41) 40 (38, 40) 40 (40, 41) 40 (40, 41) NA 
Birth length [Mean 
(sd)], cm 51 (2) 51.31 (2.50) NA NA NA 
Ponderal index [Mean 
(sd)], kg/m3 26 (3) 25.68 (3.40) NA NA NA 
REFERENCES 
Reference - cohort 
MOTHERS: Fraser, A. et al. 
(2013) Cohort Profile: the 
Avon Longitudinal Study of 
Parents and Children: 
ALSPAC mothers cohort. Int 
J Epidemiol. 42(1):97-110.17    
CHILDREN: Boyd A et al. 
(2013). Cohort Profile: the 
'children of the 90s'--the 
index offspring of the Avon 
Longitudinal Study of 
Parents and Children. Int J 
Epidemiol. 42(1):111-27.18 
a) Schlemm et al., J 
Hypertens. 2010 
Apr;28(4):732-919 
b) Hocher et al., 
Pharmacogenet 
Genomics. 2009 
Sep;19(9):710-8.,20 
c) Pfab et al., 
Circulation. 2006 Oct 
17;114(16):1687-9221 
Power C, Elliott J.  
Cohort profile: 1958 
British birth cohort 
(National Child 
Development Study).  
Int J Epidemiol 2006; 
35(1):34-4122 
Power C, Elliott J.  
Cohort profile: 1958 
British birth cohort 
(National Child 
Development Study).  
Int J Epidemiol 2006; 
35(1):34-4122,23 
Zhao et al., 2009 
Examination of type 
2 diabetes loci 
implicates CDKAL1 
as a birth weight 
gene. Diabetes 
58(10): 2414-824 
Study URL http://www.bristol.ac.uk/alspac/ a NA 
www.cls.ioe.ac.uk and 
www.wtccc.org.uk www.cls.ioe.ac.uk  NA 
aPlease note that the study website contains searchable details of all data, available through: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/ 
NA, not available 
Informed consent was obtained from all participants, and study protocols were approved by the local regional or institutional ethics committees (ethical approval for the study was obtained 
from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees) 
.
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eTable 1(b) Basic characteristics of study participants and their offspring (studies 6-10) 
  
STUDY COPSAC-2000 Mothers DNBC-GOYA Random Set 
DNBC-PTB-CONTROL 
Mothers  EFSOCH Mothers GEN-3G Mothers 
STUDY 
INFORMATION 
Ethnicity Danish/European descent Danish/European descent Danish/European descent British/European descent Canadian/European descent 
Country (Sample source) Denmark Denmark Denmark UK Canada 
Collection type (e.g. 
population-based) 
High-risk asthma birth 
cohort Population based
a Population-based  Community-based Population-based 
N women with birth 
weight of 1 child and 
genotypes for at least one 
genetic score 
282 1,805 1,649 746 676 
Year(s) of birth  of 
offspring  1998 -  2001 1996-2002 1987-2009 2000-2004 2010-2013 
Fetal  genotype data 
available? (Y/N) Y N Y Y N 
BIRTH WEIGHT 
Method by which 
offspring birth weight 
(and length, if available) 
were collected 
Medical Records Obstetric data from medical birth register 
Obstetric data from 
medical birth register 
At birth using standard 
neonatal anthropometry 
measures 
Hospital electronic 
medical records 
GESTATIONAL AGE 
Method by which 
gestational age was 
collected 
Medical Records 
The National Birth 
Register, where gestational 
age is reported by doctors 
and midwives at birth 
Consensus algorithm for 
gestational age was 
developed based on 
information from medical 
birth register, hospital 
discharge register, LMP, 
LMP corrected for 
menstrual cycle length, 
Expected date of delivery 
(often based on 
ultrasound), and mother's 
selfreport of gestational 
age.  
Hospital records and study 
midwives 
Hospital electronic 
medical records 
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 COPSAC-2000 Mothers DNBC-GOYA Random Set 
DNBC-PTB-CONTROL 
Mothers  EFSOCH Mothers GEN-3G Mothers 
SUMMARY 
MATERNAL 
CHARACTERISTICS, 
where available in the 
INCLUDED sample, 
DURING 
PREGNANCY 
(median (IQR) given 
where the trait 
distribution deviates 
strongly from the 
normal distribution 
Maternal age at delivery, 
unless otherwise stated 
[Mean (sd)], years  
30.4 (4.3) 29.2 (4.2) 29.9 (4.2) 30.5 (5.3) 28.4 (4.4) 
Maternal pre-pregnancy 
BMI [Mean (sd)], kg/m2  NA 23.57 (4.27) 23.57 (4.27) 24.07 (4.42) 24.83 (5.63) 
Maternal pregnancy BMI 
[Mean (sd)], kg/m2 NA NA NA 28.01 (4.55) 27.98 (5.38) 
Fasting glucose [Mean 
(sd)], mmol/L NA NA NA 4.35 (0.38) 4.20 (0.41) 
Triglycerides [Mean (sd)], 
mmol/L   NA NA NA 2.13 (0.73) 1.93 (0.64) 
HDL-cholesterol [Mean 
(sd)], mmol/L NA NA NA 2.08 (0.46) 1.91 (0.43) 
Blood pressure [Mean 
(sd)], mmHg NA NA NA NA 107.5 (9.2) / 67.6 (6.8) 
25-hydroxyvitamin D 
[Median (IQR)], nmol/L   NA NA NA NA 
61.7 [50.1 ; 75.5] (at ~9 
weeks) 
Adiponectin [Mean (sd)], 
ug/mL NA NA NA NA 12.57 (4.72) 
N (%) of mothers who 
smoked in pregnancy 36 (12.8%) 465 (25.8%) 294 (17.8%) 97 (13.0%) 59 (8.88%) 
Mean gestational week of  
collection of maternal 
characteristics 
NA NA NA 28 ~26 
N (%) parity  
primiparous births) 178 (63.2%) 903 (50.0%) 510 (30.9%) 372 (49.8%) 321 (47.5%) 
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 COPSAC-2000 Mothers DNBC-GOYA Random Set 
DNBC-PTB-CONTROL 
Mothers  EFSOCH Mothers GEN-3G Mothers 
SUMMARY  
OFFSPRING 
CHARACTERISTICS 
(offspring of the 
INCLUDED sample of 
mothers) 
Birth weight [Mean (sd) ], 
grams 3560 (505) 3643 (495) 3595 (497) 3512 (480) 3448 (433) 
Gestational age at 
delivery [Median (IQR)], 
weeks 
40 (39, 41) 40.3 (39.4 , 41.1) 40 (39, 40) 40 (37, 43) 39.7 [38.9, 40.4] 
Birth length [Mean (sd)], 
cm 52.5 (2.2) 52.5 (2.2) 52 (2) 50 (2) 51.1 (2.1) 
Ponderal index [Mean 
(sd)], kg/m3 24.6 (2.4) 25.0 (2.3) 25 (2) 28 (3) 25.9 (2.5) 
REFERENCES 
Reference - cohort 
Bisgaard H. The 
Copenhagen Prospective 
Study on Asthma in 
Childhood (COPSAC): 
design, rationale, and 
baseline data from a 
longitudinal birth cohort 
study. Ann Allergy 
Asthma Immunol 
2004;93:381–389.25 
Nohr et al. (2009) PLoS 
One. 4(12):e844426 
Olsen, J., Melbye, M., 
Olsen, S. F. et al (2001). 
The Danish National Birth 
Cohort-its background, 
structure and aim. 
Scandinavian journal of 
public health, 29(4), 300-
307.27 
Knight, B., Shields, B. M., 
Hattersley, A. T. (2006). 
The Exeter Family Study 
of Childhood Health 
(EFSOCH): study protocol 
and methodology28 
Lacroix M et al. Diabetes 
Care 201329 
Study URL www.copsac.com www.dnbc.dk www.dnbc.dk www.diabetesgenes.org NA 
aPregnant women recruited 1996-2002 as part of the Danish National Birth Cohort. A random (according to BMI) selection with genotype data are included in the current study. 
NA, not available 
Informed consent was obtained from all participants, and study protocols were approved by the local regional or institutional ethics committees 
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eTable 1(c) Basic characteristics of study participants and their offspring (studies 11-14) 
  
STUDY Generation R Mothers HAPO Mothers (GWAS) HAPO  Mothers (nonGWAS) MoBa (Mothers) 
STUDY 
INFORMATION 
Ethnicity Dutch/European descent  Northern European European descent Norwegian/European descent 
Country (Sample 
source) The Netherlands UK, Canada, Australia USA, UK, Canada, Australia Norway 
Collection type (e.g. 
population-based) Population-based Population-based Population-based Population based 
N women with birth 
weight of 1 child and 
genotypes for at 
least one genetic 
score 
3,810 1,380 3,590 650 
Year(s) of birth  of 
offspring 2002-2006 2000-2006 2000-2006 1999-2008 
Fetal  genotype data 
available? (Y/N) Y Y Y Y 
BIRTH WEIGHT 
Method by which 
offspring birth 
weight (and length, 
if available) were 
collected 
Hospital records and 
community midwives Medical record abstraction Medical record abstraction 
 From The Medical Birth 
Registry of Norway 
GESTATIONAL AGE 
Method by which 
gestational age was 
collected 
Hospital records and 
community midwives 
Estimated according to last menstrual 
period or ultrasound gestational age 
and estimated date of delivery or 
confinement 
Estimated according to last menstrual 
period or ultrasound gestational age 
and estimated date of delivery or 
confinement 
Gestational age was obtained 
from ultrasound at 
gestational  week 17-19 of 
pregnancy.                                                                                                                                      
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 Generation R Mothers HAPO Mothers (GWAS) HAPO  Mothers (nonGWAS) MoBa (Mothers) 
SUMMARY 
MATERNAL 
CHARACTERISTICS, 
where available in the 
INCLUDED sample, 
DURING 
PREGNANCY 
(median (IQR) given 
where the trait 
distribution deviates 
strongly from the 
normal distribution 
Maternal age at 
delivery, unless 
otherwise stated 
[Mean (sd)], years  
31.2 (4.5) [=Maternal age at 
intake, when average 
gestational age = 14.4 weeks]  
31.5(5.3) [=Maternal age at OGTT, 
when average gestaional age = 28 
weeks] 
30.4 (5.4) [=Maternal age at OGTT, 
when average gestaional age = 28 
weeks] 
28.5 (3.3) 
Maternal pre-
pregnancy BMI 
[Mean (sd)], kg/m2  
23.12 (3.92) 24.5 (5.0) 24.63 (5.33) 23.93 (3.94) 
Maternal pregnancy 
BMI [Mean (sd)], 
kg/m2 
26.98 (4.04)  28.46 (4.82) 28.58 (5.25) 24.78 (3.80) 
Fasting glucose 
[Mean (sd)], mmol/L NA 4.56 (0.37) 4.54 (0.37) NA 
Triglycerides [Mean 
(sd)], mmol/L   NA - - NA 
HDL-cholesterol 
[Mean (sd)], mmol/L NA - - NA 
Blood pressure 
[Mean (sd)], mmHg 120.0 (11.4) / 69.3 (9.2) 108.6 (9.9) / 71.4 (8.0) 108.3 (9.6) / 70.7 (8.1) 113.5 (11.8) / 68.5 (8.4) 
25-hydroxyvitamin 
D [Median (IQR)], 
nmol/L   
NA - - NA 
Adiponectin [Mean 
(sd)], ug/mL NA 20.37(12.83) - NA 
N (%) of mothers 
who smoked in 
pregnancy 
1,033 (27.1%) 186 (13.5%) 539 (15.0%) 53 (8.1%) 
Mean gestational 
week of  collection of 
maternal 
characteristics 
30 28.5 28.3 18 
N (%) parity 
(primiparous births) 2236 (58.7%) 785 (56.9%) 1795 (50.0%) 298 (45.8%) 
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 Generation R Mothers HAPO Mothers (GWAS) HAPO  Mothers (nonGWAS) MoBa (Mothers) 
SUMMARY  
OFFSPRING 
CHARACTERISTICS 
(offspring of the 
INCLUDED sample of 
mothers) 
Birth weight [Mean 
(sd) ], grams 3528 (494)  3557 (517) 3526 (463) 3679 (430) 
Gestational age at 
delivery [Median 
(IQR)], weeks 
40 (39, 41) 40 (39, 41) 40 (39, 41) 40.1 (39.3, 41.0) 
Birth length [Mean 
(sd)], cm 51 (2)  50.6 (2.3) 50.8 (2.3) 50.6 (1.8) 
Ponderal index 
[Mean (sd)], kg/m3 27 (3)  27.48 (3.19) 26.87 (2.86) 28.31 (2.53) 
REFERENCES 
Reference - cohort 
Jaddoe, van Duijn, Franco et 
al. 2012 Eur J Epidemiol. 
27(9):739-56.23 
Metzger et al., Hyperglycemia and 
adverse pregnancy outcomes. N Engl 
J Med 2008; 358:1991–200230  
Metzger et al., Hyperglycemia and 
adverse pregnancy outcomes. N Engl 
J Med 2008; 358:1991–2002 30 
                                                           
Cohort profile: The 
Norwegian Mother and Child 
Cohort Study (MoBa) 
Per Magnus, 
 Lorentz M Irgens,  
 Kjell Haug, 
 Wenche Nystad,  
 Rolv Skjærven,
 Camilla Stoltenberg and  
  The Moba Study Group. 
Int. J. Epidemiol. (October 
2006)   35  (5):  1146-1150.31                                                   
Rønningen KS, Paltiel L, 
Meltzer HM et al. The 
biobank of the Norwegian 
Mother and Child Cohort 
Study—A Resource for the 
next 100 years.Eur J 
Epidemiol. 2006;21(8):619-
25.32 
Study URL www.generationr.nl http://www.hapo.northwestern.edu/index.html 
http://www.hapo.northwestern.edu/in
dex.html http://www.fhi.no/morogbarn 
NA, not available 
Informed consent was obtained from all participants, and study protocols were approved by the local regional or institutional ethics committees 
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eTable 1(d) Basic characteristics of study participants and their offspring (studies 15-18) 
  STUDY NFBC1966 NTR QIMR TWINSUK 
STUDY 
INFORMATION 
Ethnicity Finnish/European descent Dutch/European descent European descent European descent 
Country (Sample source) Northern Finland, Provinces of Oulu and Lapland The Netherlands Australia UK 
Collection type (e.g. 
population-based) 
Prospective general population-
based Population-based controls 
Population-based recruitment 
of adult twins population based 
N women with birth 
weight of 1 child and 
genotypes for at least one 
genetic score 
2,035 706 892 1,602 
Year(s) of birth  of 
offspring 1987-2001  1946 - 2003 1929-1990  NA 
Fetal  genotype data 
available? (Y/N) N N N N 
BIRTH WEIGHT 
Method by which 
offspring birth weight 
(and length, if available) 
were collected 
Birth Register Data 
From longitudinal surveys by 
self-report/parental report. Birth 
weight determined as  average of 
all valid data points. 
Self-report through 
questionnaire Questionnaire 
GESTATIONAL AGE 
Method by which 
gestational age was 
collected 
Last menstrual period and Scans. 
Based on hospital records   
From longitudinal surveys by 
self-report/parental report. 
Gestational age determined as  
average of all valid data points.  
NA Questionnaire 
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 NFBC1966 NTR QIMR TWINSUK 
SUMMARY 
MATERNAL 
CHARACTERISTICS, 
where available in the 
INCLUDED sample, 
DURING 
PREGNANCY 
(median (IQR) given 
where the trait 
distribution deviates 
strongly from the 
normal distribution 
Maternal age at delivery, 
unless otherwise stated 
[Mean (sd)], years  
26.5 (3.7)  available for 2010 
participants 27.1 (3.7) 24.5 (4.0) NA 
Maternal pre-pregnancy 
BMI [Mean (sd)], kg/m2  NA NA 22.79 (5.13) NA 
Maternal pregnancy BMI 
[Mean (sd)], kg/m2 NA NA NA NA 
Fasting glucose [Mean 
(sd)], mmol/L NA NA NA NA 
Triglycerides [Mean (sd)], 
mmol/L   NA NA NA NA 
HDL-cholesterol [Mean 
(sd)], mmol/L NA NA NA NA 
Blood pressure [Mean 
(sd)], mmHg NA NA NA NA 
25-hydroxyvitamin D 
[Median (IQR)], nmol/L   NA NA NA NA 
Adiponectin [Mean (sd)], 
ug/mL NA NA NA NA 
N (%) of mothers who 
smoked in pregnancy NA NA NA NA 
Mean gestational week of  
collection of maternal 
characteristics 
NA NA NA NA 
N (%) parity 
(primiparous births) NA 593 (84.0%) NA NA 
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 NFBC1966 NTR QIMR TWINSUK 
SUMMARY  
OFFSPRING 
CHARACTERISTICS 
(offspring of the 
INCLUDED sample of 
mothers) 
Birth weight [Mean (sd) ], 
grams 3525 (461) 3469 (529) 3344 (532) 3365 (581) 
Gestational age at 
delivery [Median (IQR)], 
weeks 
40 (39, 41) 40 (38, 42) NA NA 
Birth length [Mean (sd)], 
cm 50.3 (2.0) NA NA NA 
Ponderal index [Mean 
(sd)], kg/m3 27.61 (2.44) NA NA NA 
REFERENCES 
Reference - cohort 
Rantakallio P. Groups at risk in 
low birth weight infants and 
perinatal mortality. Acta Paediatr 
Scand 1969;193(suppl 193):1–
71;33 Järvelin M-R., Sovio U., 
King V., Laurén L., Xu B., 
McCarthy M., Hartikainen A-L., 
Laitinen J., Zitting P., Rantakallio 
P., Elliott P.: Early Life Factors 
and Blood Pressure at Age 31 
Years in the 1966 Northern 
Finland Birth Cohort. 
Hypertension 44:838-846, 2004.34  
[1] Boomsma DI et al. 
Netherlands Twin Register: from 
twins to twin families. Twin 
Research and  Human Genetics. 
2006, 9, 849-5735; [2] Willemsen 
et al. The Adult Netherlands Twin 
Register: twenty-five years of 
survey and biological data 
collection. Twin Research and 
Human Genetics, 2013, 16, 271-
8136. 
Medland SE et al. (2009) 
Common variants in the 
trichohyalin gene are 
associated with straight hair 
in Europeans. American 
Journal of Human Genetics 
85:750-755.37 
[1] Moayyeri A, Hammond 
CJ, Hart DJ, et al., 2013, 
The UK Adult Twin 
Registry (TwinsUK 
Resource)., Twin Research 
and Human Genetics, 
Vol:16, ISSN:1832-4274, 
Pages:144-149 38                              
[2] Moayyeri A, Hammond 
CJ, Valdes AM, et al., 2013, 
Cohort Profile: TwinsUK 
and healthy ageing twin 
study., Int J Epidemiol, 
Vol:42, 0300-5771, 
Pages:76-85 39 
Study URL http://www.oulu.fi/nfbc/  www.tweelingenregister.org http//www.genepi.qimr.edu.au/general/researchtopics.cgi www.twinsuk.co.uk 
NA, not available 
Informed consent was obtained from all participants, and study protocols were approved by the local regional or institutional ethics committees 
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eTable 2(a) Genotyping information (studies 1-5) 
  
STUDY ALSPAC  Mothers Berlin Birth Cohort (BBC) Mothers 
1958 British Birth 
Cohort or NCDS 
(B58C-WTCCC) 
1958 British Birth 
Cohort or NCDS 
(B58C-T1DGC) 
CHOP Mothers 
MATERNAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel 
Illumina Human660W-
Quad BeadChip  Human Exomechip ver1.1 
Affymetrix Genome-
wide Human SNP Array 
6.0 
Illumina 550K Infinium Illunina550, Illumina610 Infinium 
Genotyping centre 
Centre National de 
Génotypage (CNG), 
Evry, France 
Oxfor Centre for Diabete, 
Endocrinology and 
Metabolism, University of 
Oxford, UK 
Wellcome Trust Sanger 
Institute, Cambridge, 
UK 
JDRF/WT DIL Lab in 
Cambridge, UK 
The Center for Applied 
Genomics, Children's 
Hospital of 
Philadelphia, USA 
N SNPs in QC'd dataset 526,688 NA 721,428 520,413 513,518 
Imputation software / 
reference panel 
MACH v.1.0.16 / 
HapMap Phase II NA 
Impute /HapMap Phase 
II 
Impute /HapMap Phase 
II 
Impute /HapMap Phase 
II 
N QC'd SNPs available 
for GWAS analysis 2,450,866 NA 2,543,926 2,451,644 2,546,219 
Genomic control lambda 
from GWAS analysis of 
offspring birth weight 
1.039 NA 0.984 1.007 NA 
FETAL GENOME- 
OR EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel 
Illumina 
HumanHap550 quad 
array 
Human Exomechip ver1.1  NA NA  Illunina550, Illumina610 Infinium 
Genotyping centre 
Sample Logistics and 
Genotyping Facilities 
at the Wellcome Trust 
Sanger Institute and 
LabCorp (Laboratory 
Corportation of 
America) using support 
from 23andMe 
Oxford Centre for Diabete, 
Endocrinology and 
Metabolism, University of 
Oxford, UK 
 NA  NA The Center for Applied Genomics 
N SNPs in QC'd dataset 500,541 NA  NA  NA 513,518 
Imputation software / 
reference panel 
MACH v.1.0.16 / 
HapMap Phase II NA  NA  NA 
Impute /HapMap Phase 
II 
DATA ANALYSIS Analysis software Stata v.13 PLINK and R Stata, version 12 Stata, version 12 SNPtest and R 
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 ALSPAC  Mothers Berlin Birth Cohort (BBC) Mothers 
1958 British Birth 
Cohort or NCDS 
(B58C-WTCCC) 
1958 British Birth 
Cohort or NCDS 
(B58C-T1DGC) 
CHOP Mothers 
REFERENCES Reference - MATERNAL genotyping 
Evans DM et al. (2013) 
Genome-wide 
association study 
identifies loci affecting 
blood copper, selenium 
and zinc. Hum Mol 
Genet. 22(19):3998-
4006.40 
NA 
Sawcer S, Hellenthal G, 
Pirinen M, Spencer CC, 
Patsopoulos NA, et al. 
(2011) Genetic risk and 
a primary role for cell-
mediated immune 
mechanisms in multiple 
sclerosis. Nature 476: 
214–21941 
Barrett JC, Clayton DG, 
Concannon P et al.  
Genome-wide assocition 
study and meta-analysis 
find that over 40 loci 
affect risk of type 1 
diabetes. Nat. Genet 
200942 
NA 
REFERENCES Reference -FETAL genotyping 
Paternoster L. et al. 
(2012) Genome-wide 
association study of 
three-dimensional 
facial morphology 
identifies a variant in 
PAX3 associated with 
nasion position. Am J 
Hum Genet. 90(3):478-
85.43 
NA NA NA NA 
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eTable 2(b) Genotyping information (studies 6-10) 
 STUDY COPSAC-2000 Mothers 
DNBC-GOYA Random 
Set 
DNBC-PTB-CONTROL 
Mothers EFSOCH Mothers GEN-3G Mothers 
MATERNAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform 
and SNP panel Illumina 550K 
Illumina Human610-
Quad v1.0 
Illumina Human 660W-quad 
Bead Array 
Illumina Human 
Exome Beadchip v1 NA 
Genotyping centre 
Children's Hospital of 
Philadelphia, Center for 
Applied Genomics 
Centre National de 
Génotypage (CNG), 
Evry, France 
Center for Inherited Disease 
Research, Johns Hopkins 
University, Baltimore, 
Maryland, USA 
Centre National de 
Génotypage, France NA 
N SNPs in QC'd 
dataset 486,373 545,349 518,097 234,763 NA 
Imputation software / 
reference panel 
MacH-minimac/Hapmap 
Phase II Mach 1.0 MaCH/HapMap Phase II NA NA 
N QC'd SNPs 
available for GWAS 
analysis 
NA 2,449,993 2,543,887 
57 QC'd SNPs 
available for analysis 
of genetic scores 
selected for the current 
project 
NA 
Genomic control 
lambda from GWAS 
analysis of offspring 
birth weight 
NA 1.006 1.006 NA NA 
MATERNAL 
CUSTOM 
GENOTYPING 
Genotyping centre 
and method NA NA NA 
LGC Genomics 
(formerly 
Kbiosciences); KASPar 
Genome Quebec 
Innovation Centre 
Call rate [Median 
(range)]; N SNPs 
genotyped 
NA NA NA 0.953 [0.932, 0.999]      (N=16 SNPs) 
0.99 [0.98 ; 1] (N=4 
snps) 
Did any SNPs deviate 
from HWE 
(Bonferroni corrected 
P<0.05)? Y/N 
NA NA NA N N 
Duplicate 
concordance (%) NA NA NA >99% (approx. 10%) 100% 
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  COPSAC-2000 Mothers 
DNBC-GOYA Random 
Set 
DNBC-PTB-CONTROL 
Mothers EFSOCH Mothers GEN-3G Mothers 
FETAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform 
and SNP panel Illumina 550K NA 
Illumina Human 660W-quad 
Bead Array NA NA 
Genotyping centre 
Children's Hospital of 
Philadelphia, Center for 
Applied Genomics 
NA 
Center for Inherited Disease 
Research, Johns Hopkins 
University, Baltimore, 
Maryland, USA 
NA NA 
N SNPs in QC'd 
dataset 486,373 NA 514,382 NA NA 
Imputation software / 
reference panel 
MacH-minimac/Hapmap 
Phase II NA MaCH/HapMap Phase II NA NA 
FETAL 
CUSTOM 
GENOTYPING 
Genotyping centre 
and method NA NA NA 
LGC Genomics 
(formerly 
Kbiosciences); KASPar 
NA 
Call rate [Median 
(range)]; N SNPs 
genotyped 
NA NA NA 0.926 [0.907, 0.934]      (N=13 SNPs) NA 
Did any SNPs deviate 
from HWE 
(Bonferroni corrected 
P<0.05)? Y/N 
NA NA NA N NA 
Duplicate 
concordance (% 
duplicated genotypes) 
NA NA NA >99% (approx. 10%) NA 
DATA 
ANALYSIS Analysis software R-project Stata R Stata v.13 R 
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  COPSAC-2000 Mothers 
DNBC-GOYA Random 
Set 
DNBC-PTB-CONTROL 
Mothers EFSOCH Mothers GEN-3G Mothers 
REFERENCES 
Reference - 
MATERNAL 
genotyping 
HakonarsonH,GrantSF,B
radfieldJP,MarchandL,Ki
mCE,GlessnerJT, Grabs 
R, Casalunovo T, Taback 
SP, Frackelton EC, et al. 
A genome- wide 
association study 
identifies KIAA0350 as a 
type 1 diabetes gene. 
Nature 2007;448:591–
594.44 
Paternoster et al. (2011) 
PLoS One. 6(9):e24303 
Ryckman, K. K., Feenstra, 
B., Shaffer, J. R., et al 
(2012). Replication of a 
genome-wide association 
study of birth weight in 
preterm neonates. The 
Journal of pediatrics, 
160(1), 19-24.45 
NA NA 
REFERENCES Reference -FETAL genotyping 
HakonarsonH,GrantSF,B
radfieldJP,MarchandL,Ki
mCE,GlessnerJT, Grabs 
R, Casalunovo T, Taback 
SP, Frackelton EC, et al. 
A genome- wide 
association study 
identifies KIAA0350 as a 
type 1 diabetes gene. 
Nature 2007;448:591–
594.44 
NA 
Ryckman, K. K., Feenstra, 
B., Shaffer, J. R., et al 
(2012). Replication of a 
genome-wide association 
study of birth weight in 
preterm neonates. The 
Journal of pediatrics, 
160(1), 19-24.45 
NA NA 
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eTable 2(c) Genotyping information (studies 11-14) 
 STUDY Generation R Mothers HAPO Mothers (GWAS) HAPO  Mothers (nonGWAS) MoBa (Mothers) 
MATERNAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel NA 
Illumina Human 610 Quad 
v1 B SNP array NA Illumina 660Wquad 
Genotyping centre NA 
Broad Institute Center for 
Genotyping and Analysis 
(CGA), USA 
NA The Norwegian Cancer Hospital, Oslo 
N SNPs in QC'd dataset NA 559,739 NA 432,270 
Imputation software / 
reference panel NA 
Beagle / HapMap3 CEU & 
TSI NA 
PLINK /HapMap Phase 
II 
N QC'd SNPs available for 
GWAS analysis NA 1,968,447 NA NA 
Genomic control lambda 
from GWAS analysis of 
offspring birth weight 
NA 1.016 NA None 
MATERNAL 
CUSTOM 
GENOTYPING 
Genotyping centre and 
method 
LGC Genomics (formerly 
Kbiosciences); KASPar NA 
LGC Genomics (formerly 
Kbiosciences); KASPar NA 
Call rate [Median (range)]; 
N SNPs genotyped 99.3% (N=34 snps) NA 
0.983 [0.977, 0.988] 
(N=23 SNPs) NA 
Did any SNPs deviate from 
HWE (Bonferroni corrected 
P<0.05)? Y/N 
Y: rs4836133 (P = 3x10-15; 
excluded) NA N NA 
Duplicate concordance (% 
duplicated genotypes) 99.80% NA >=99% (min 4%) NA 
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  Generation R Mothers HAPO Mothers (GWAS) HAPO  Mothers (nonGWAS) MoBa (Mothers) 
FETAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel Ilumina 610 Quad and 660W 
Illumina Human 610 Quad 
v1 B SNP array NA Illumina 660Wquad 
Genotyping centre 
Human Genotyping Facility 
(HuGeF), Dept Internal 
Medicine, Erasmus MC, The 
Netherlands 
Broad Institute Center for 
Genotyping and Analysis 
(CGA) 
NA The Norwegian Cancer Hospital, Oslo 
N SNPs in QC'd dataset 489,879 559,739 NA 432270 
Imputation software / 
reference panel Minimac and MACH 
Beagle / HapMap3 CEU & 
TSI NA 
PLINK /HapMap Phase 
II 
FETAL 
CUSTOM 
GENOTYPING 
Genotyping centre and 
method NA NA 
LGC Genomics (formerly 
Kbiosciences); KASPar NA 
Call rate [Median (range)]; 
N SNPs genotyped NA NA 
0.983 [0.977, 0.988] 
(N=23 SNPs) NA 
Did any SNPs deviate from 
HWE (Bonferroni corrected 
P<0.05)? Y/N 
NA NA N NA 
Duplicate concordance (%) NA NA >=99% (min 4%) NA 
DATA 
ANALYSIS Analysis software Stata version 12 R 3.0.2 Stata v.13 IBM SPSS Statistics 20 
REFERENCES Reference - MATERNAL genotyping NA 
Hayes et al., Identification of 
HKDC1 and BACE2 as 
genes influencing glycemic 
traits during pregnancy 
through genome-wide 
association studies.  
Diabetes. 2013 
Sep;62(9):3282-9146 
NA NA 
REFERENCES Reference -FETAL genotyping 
Jaddoe, van Duijn, Franco et 
al. 2012 Eur J Epidemiol. 
27(9):739-56.23 
Urbanek et al., The 
chromosome 3q25 genomic 
region is associated with 
measures of adiposity in 
newborns in a multi-ethnic 
genome-wide association 
study.Hum Mol Genet. 2013 
Sep 1;22(17):3583-96.47 
NA NA 
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eTable 2(d) Genotyping information (studies 16-18) 
 STUDY NFBC1966 NTR QIMR TWINSUK 
MATERNAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel 
Illumina HumanCNV-
370DUO Analysis BeadChip 
Perlegen-Affymetrix, 
Affymetrix 6.0, Illumina 
370K, 600K, 1M Omni 
HumanCNV370-Quadv3 
HumanHap3001,2, 
HumanHap610Q, 1M-Duo 
and 1.2MDuo 1M 
Genotyping centre Broad Institute 
Perlegen Sciences Mountain 
View CF USA, Finnish 
Genome Center Helsinki 
Finland, SNP technology 
Platform Uppsala Sweden, 
Molecular Epidemiology 
Leiden The Netherlands, 
Translational Genomics 
Research Institute Phoenix 
AZ USA, Institute of Human 
Genetics LIFE & BRAIN 
Center Bonn Germany. 
CIDR Sanger 
N SNPs in QC'd dataset 324,896 312,214-814,708 
323,093, reduced to a 
common set of 274,604 
SNPs (across the QIMR 
sample) 
up to 874,733 SNPs 
Imputation software / 
reference panel Impute version 2 / HapMap2 
Impute 1.0 / Build 36r24 
Hapmap 2 MACH/HapMap Phase II 
IMPUTE software package 
(v2) 5 using two 
referencepanels, P0 
(HapMap2, rel 22, 
combined 
CEU+YRI+ASN panels) 
and P1 (610k+, including 
combinedHumanHap610k 
and 1M reduced to 610k 
SNP content). 
N QC'd SNPs available for 
GWAS analysis 2,487,934 2385474 2,454,244 2,401,373 
Genomic control lambda 
from GWAS analysis of 
offspring birth weight 
1.020 1.002 1.012 1 
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  NFBC1966 NTR QIMR TWINSUK 
FETAL 
GENOME- OR 
EXOME-WIDE 
GENOTYPING 
Genotyping platform and 
SNP panel NA 
Perlegen-Affymetrix, 
Affymetrix 6.0, Illumina 
370K, 600K, 1M Omni 
NA NA 
Genotyping centre NA 
Perlegen Sciences Mountain 
View CF USA, Finnish 
Genome Center Helsinki 
Finland, SNP technology 
Platform Uppsala Sweden, 
Molecular Epidemiology 
Leiden The Netherlands, 
Translational Genomics 
Research Institute Phoenix 
AZ USA, Institute of Human 
Genetics LIFE & BRAIN 
Center Bonn Germany. 
NA NA 
N SNPs in QC'd dataset NA 312214-814708 NA NA 
Imputation software / 
reference panel NA 
Impute 1.0 / Build 36r24 
Hapmap 2 NA NA 
DATA ANALYSIS Analysis software R 2.14.2 Stata R SNPTEST , Stata 
REFERENCES Reference - MATERNAL genotyping 
Sabatti et al. Genome-wide 
association analysis of 
metabolic traits in a birth 
cohort from a founder 
population. Nat Genet. 
2009;41:35-46 and 
Prokopenko et al. Variants 
in MTNA1B influence 
fasting glucose levels. Nat 
Genet 2009;41:77-81.48 
[1] Willemsen et al. The 
Netherlands Twin Register 
biobank: a resource for 
genetic epidemiological 
studies. Twin Research and 
Human Genetics. 2010, 13, 
231-45.36 
Medland SE et al. (2009) 
Common variants in the 
trichohyalin gene are 
associated with straight hair 
in Europeans. American 
Journal of Human Genetics 
85:750-755.37 
Moayyeri A, Hammond 
CJ, Hart DJ, et al., 2013, 
The UK Adult Twin 
Registry (TwinsUK 
Resource)., Twin Research 
and Human Genetics, 
Vol:16, ISSN:1832-4274, 
Pages:144-14938 
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eTable 3. Details of single nucleotide polymorphisms (SNPs) used to construct the genetic scores 
Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Adiponectin rs17300539 ADIPOQ A G 0.330 Units: age- and sex-
adjusted z-scores. 
Source: Yaghootkar et 
al (2013) Diabetes 
62(10):3589-9849 
 
Adiponectin rs3774261 ADIPOQ A G 0.354 
Adiponectin rs3821799 ADIPOQ C T 0.352 
       
BMI rs10150332 NRXN3 C T 0.13 
Units: kg/m2 increase 
Source: Speliotes et 
al., Nature Genetics 
(2010)50 
BMI rs10767664 BDNF A T 0.19 
BMI rs10938397 GNPDA2 G A 0.18 
BMI rs10968576 LRRN6C G A 0.11 
BMI rs11847697 PRKD1 T C 0.17 
BMI rs12444979 GPRC5B C T 0.17 
BMI rs13078807 CADM2 G A 0.1 
BMI rs1514175 TNNI3K A G 0.07 
BMI rs1555543 PTBP2 C A 0.06 
BMI rs1558902 FTO A T 0.39 
BMI rs206936 NUDT3 G A 0.06 
BMI rs2112347 FLJ35779 T G 0.1 
BMI rs2241423 MAP2K5 G A 0.13 
BMI rs2287019 QPCTL C T 0.15 
BMI rs2815752 NEGR1 A G 0.13 
BMI rs2867125 TMEM18 C T 0.31 
BMI rs2890652 LRP1B C T 0.09 
BMI rs29941 KCTD15 G A 0.06 
BMI rs3810291 TMEM160 A G 0.09 
BMI rs3817334 MTCH2 T C 0.06 
BMI rs4771122 MTIF3 G A 0.09 
BMI rs4836133 ZNF608 A C 0.07 
BMI rs4929949 RPL27A C T 0.06 
BMI rs543874 SEC16B G A 0.22 
BMI rs571312 MC4R A C 0.23 
BMI rs713586 RBJ C T 0.14 
BMI rs7138803 FAIM2 A G 0.12 
BMI rs887912 FANCL T C 0.1 
BMI rs9816226 ETV5 T A 0.14 
BMI rs987237 TFAP2B G A 0.13 
       
30	
	
Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Blood pressure rs2932538 MOV10 G A 0.3884 
Units: mmHg per BP-
raising allele; 
Sources: Ehret et al 
2010 Nature15; 
Johnson et al 2010 
Hypertension51; Wain 
et al 2010 Nat 
Genet.52 
Blood pressure rs13082711 SLC4A7 C T 0.3151 
Blood pressure rs419076 MECOM T C 0.4088 
Blood pressure rs13139571 GUCY1A3-GUCY1B3 C A 0.3213 
Blood pressure rs1173771 NPR3-C5orf23 G A 0.5041 
Blood pressure rs11953630 EBF1 C T 0.4119 
Blood pressure rs805303 BAT2-BAT5 G A 0.3756 
Blood pressure rs4373814 CACNB2(5') C G 0.3726 
Blood pressure rs932764 PLCE1 G A 0.4837 
Blood pressure rs7129220 ADM A G 0.6186 
Blood pressure rs633185 FLJ32810-TMEM133 C G 0.5647 
Blood pressure rs2521501 FURIN-FES T A 0.6498 
Blood pressure rs17608766 GOSR2 C T 0.5564 
Blood pressure rs1327235 JAG1 G A 0.3404 
Blood pressure rs6015450 GNAS-EDN3 G A 0.8964 
Blood pressure rs17367504 MTHFR-NPPB A G 0.9031 
Blood pressure rs3774372 ULK4 C T 0.0666 
Blood pressure rs1458038 FGF5 T C 0.7057 
Blood pressure rs1813353 CACNB2(3') T C 0.5686 
Blood pressure rs4590817 C10orf107 G C 0.6457 
Blood pressure rs11191548 CYP17A1-NT5C2 T C 1.0952 
Blood pressure rs381815 PLEKHA7 T C 0.5747 
Blood pressure rs17249754 ATP2B1 G A 0.9282 
Blood pressure rs3184504 SH2B3 T C 0.5976 
Blood pressure rs10850411 TBX5-TBX3 T C 0.3541 
Blood pressure rs1378942 CYP1A1-ULK3 C A 0.6125 
Blood pressure rs12940887 ZNF652 T C 0.3622 
Blood pressure rs1801253 ADRB1 C G 0.57 
Blood pressure rs13002573 FIGN A G 0.416 
Blood pressure rs17477177 PIK3CG C T 0.552 
Blood pressure rs1446468 FIGN C T 0.499 
Blood pressure rs319690 MAP4 (intron) T C 0.423 
Blood pressure rs2782980 ADRB1 C T 0.406 
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Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Fasting Glucose rs560887 G6PC2 C T 0.075 
Units: mmol/L per 
fasting glucose raising 
allele                                   
Source: Dupuis et al., 
2010 Nature 
Genetics53 
Fasting Glucose rs13266634 SLC30A8 C T 0.027 
Fasting Glucose rs11708067 ADCY5 A G 0.027 
Fasting Glucose rs10830963 MTNR1B G C 0.067 
Fasting Glucose rs2191349 DGKB/TMEM195 T G 0.03 
Fasting Glucose rs7944584 MADD A T 0.021 
Fasting Glucose rs10885122 ADRA2A G T 0.022 
Fasting Glucose rs11605924 CRY2 A C 0.015 
Fasting Glucose rs340874 PROX1 C T 0.013 
Fasting Glucose rs11920090 SLC2A2 T A 0.02 
Fasting Glucose rs7034200 GLIS3 A C 0.018 
Fasting Glucose rs11071657 C2CD4B A G 0.008 
Fasting Glucose rs4607517 GCK A G 0.062 
       
HDL-specificb  
 rs1532085 LIPC A G 1.45 
Units: mg/dL per 
HDL raising allele                                       
Source: Teslovich et 
al., (2010) Nature 
Genetics2 
HDL-specific  
 rs16942887 LCAT A G 1.27 
HDL-specific  
 rs1883025 ABCA1 C T 0.94 
HDL-specific  
 rs3764261 CETP A C 3.39 
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Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Triglyceride main 
effectc rs10761731 JMJD1C A T 2.38 
Units: mg/dL per 
triglyceride raising 
allele                                                          
Source: Teslovich et 
al., (2010) Nature 
Genetics2 
Triglyceride main 
effect rs10889353 DOCK7 A C 4.94 
Triglyceride main 
effect rs11613352 LRP1 C T 2.7 
Triglyceride main 
effect rs11649653 CTF1 C G 2.13 
Triglyceride main 
effect rs13238203 TYW1B C T 7.91 
Triglyceride main 
effect rs1495741 NAT2 G A 2.97 
Triglyceride main 
effect rs2068888 CYP26A1 G A 2.28 
Triglyceride main 
effect rs2412710 CAPN3 A G 7 
Triglyceride main 
effect rs2929282 FRMD5 T A 5.13 
Triglyceride main 
effect rs2954029 TRIB1 A T 5.64 
Triglyceride main 
effect rs328 LPL C G 13.64 
Triglyceride main 
effect rs442177 KLHL8 T G 2.25 
Triglyceride main 
effect rs5756931 PLA2GS T C 1.54 
Triglyceride main 
effect rs645040 MSL2L1 T G 2.22 
Triglyceride main 
effect rs714052 BAZ1B A G 7.91 
Triglyceride main 
effect rs964184 APOA1 G C 16.95 
Triglyceride main 
effect rs9686661 MAP3K1 T C 2.57 
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Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Type 2 diabetes rs10203174 THADA C T 0.131 
Units: Natural 
logarithm of odds 
ratio for type 2 
diabetes per type 2 
diabetes increasing 
allele              Source: 
Morris et al., (2012) 
Nature Genetics54 
Type 2 diabetes rs10758593 GLIS3 A G 0.058 
Type 2 diabetes rs10811661 CDKN2A/B T C 0.166 
Type 2 diabetes rs10842994 KLHDC5 C T 0.095 
Type 2 diabetes rs10923931 NOTCH2 T G 0.077 
Type 2 diabetes rs11063069 CCND2 G A 0.077 
Type 2 diabetes rs1111875 HHEX/IDE C T 0.104 
Type 2 diabetes rs11257655 CDC123/CAMK1D T C 0.068 
Type 2 diabetes rs11634397 ZFAND6 G A 0.049 
Type 2 diabetes rs11717195 ADCY5 T C 0.104 
Type 2 diabetes rs12242953 VPS26A G A 0.068 
Type 2 diabetes rs12427353 HNF1A (TCF1) G C 0.077 
Type 2 diabetes rs12497268 PSMD6 G C 0.030 
Type 2 diabetes rs12571751 ZMIZ1 A G 0.077 
Type 2 diabetes rs12899811 PRC1 G A 0.077 
Type 2 diabetes rs1359790 SPRY2 G A 0.077 
Type 2 diabetes rs1496653 UBE2E2 A G 0.086 
Type 2 diabetes rs1552224 ARAP1 (CENTD2) A C 0.104 
Type 2 diabetes rs163184 KCNQ1 G T 0.086 
Type 2 diabetes rs16927668 PTPRD T C 0.039 
Type 2 diabetes rs17168486 DGKB T C 0.104 
Type 2 diabetes rs17301514 ST64GAL1 A G 0.049 
Type 2 diabetes rs17791513 TLE4 A G 0.113 
Type 2 diabetes rs17867832 GCC1 T G 0.086 
Type 2 diabetes rs1801282 PPARG C G 0.122 
Type 2 diabetes rs2007084 AP3S2 G A 0.020 
Type 2 diabetes rs2075423 PROX1 G T 0.068 
Type 2 diabetes rs2261181 HMGA2 T C 0.122 
Type 2 diabetes rs2334499 DUSP8 T C 0.039 
Type 2 diabetes rs243088 BCL11A T A 0.068 
Type 2 diabetes rs2447090 SRR A G 0.039 
Type 2 diabetes rs2796441 TLE1 G A 0.068 
Type 2 diabetes rs3734621 KCNK16 C A 0.068 
Type 2 diabetes rs3802177 SLC30A8 G A 0.131 
Type 2 diabetes rs4299828 ZFAND3 A G 0.039 
Type 2 diabetes rs4402960 IGF2BP2 T G 0.122 
Type 2 diabetes rs4430796 HNF1B (TCF2) A G 0.095 
Type 2 diabetes rs4458523 WFS1 G T 0.095 
Type 2 diabetes rs4502156 C2CD4A T C 0.058 
Type 2 diabetes rs459193 ANKRD55 G A 0.077 
Type 2 diabetes rs4812829 HNF4A A G 0.058 
Type 2 diabetes rs516946 ANK1 C T 0.086 
Type 2 diabetes rs5215 KCNJ11 C T 0.068 
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Type 2 diabetes rs6819243 MAEA T C 0.068 
Type 2 diabetes rs6878122 ZBED3 G A 0.095 
Type 2 diabetes rs7177055 HMG20A A G 0.077 
Type 2 diabetes rs7202877 BCAR1 T G 0.113 
Type 2 diabetes rs7569522 RBMS1 A G 0.048 
Type 2 diabetes rs7756992 CDKAL1 G A 0.157 
Type 2 diabetes rs7845219 TP53INP1 T C 0.058 
Type 2 diabetes rs7903146 TCF7L2 T C 0.329 
Type 2 diabetes rs7955901 TSPAN8/LGR5 C T 0.068 
Type 2 diabetes rs8108269 GIPR G T 0.068 
Type 2 diabetes rs8182584 PEPD T G 0.039 
Type 2 diabetes rs849135 JAZF1 G A 0.104 
       
Trait SNP Nearest/nearby gene 
Trait-
raising 
allelea 
Trait-
lowering 
allelea 
Beta for 
weighting 
genetic 
score 
Units of beta and 
source (including 
any extra details) 
Vitamin D - synthesis rs10741657 CYP2R1 A G 0.03 
Units: nmol/L per 
vitamin D raising 
allele                                                   
Source: Wang et al., 
(2010) Lancet55 Vitamin D - synthesis rs12785878 DHCR7/NADSYN1 T G 0.05 
a Based on the positive strand according to HapMap Phase 2 
b HDL-specific SNPs were selected due to being near genes with known Mendelain lipid disorder 
c Triglyceride main effect SNPs were included in the genetic score if they were solely associated with triglyceride levels, or if their 
effect on triglyceride levels was at least three times greater than that of HDL-, LDL- or total cholesterol (using Teslovich et al 
2010, Nat Genet 2). 
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eTable 4. Studies with maternal traits ascertained during pregnancy (or for BMI, pre-pregnancy) and 
available for association analysis with genetic scores 
Trait Total N women 
N 
Studie
s  
Study Name Time of ascertainment 
Brief description of maternal phenotype 
ascertainment and reference, if available 
BMI 11,822 5 
ALSPAC 
Mothers Pre-pregnancy  
Self-reported weight and height, weight validated 
with clinic measure (Lawlor et al., (2010) 
Diabetologia 53: 89-97)56 
DNBC-
GOYA 
Random Set 
Pre-pregnancy Registry data  (Olsen et al., (2001) Scandinavian Journal of Public Health 29:300-307)27 
DNBC-PTB-
CONTROL 
Mothers 
Pre-pregnancy Registry data  (Olsen et al., (2001) Scandinavian Journal of Public Health 29:300-30727 
EFSOCH 
Mothers Pre-pregnancy  
Measured height 3 times and averaged, pre-
pregnancy weight self reported (Knight et al., (2006) 
Paediatric Perinal Epidemiology 20:172-179)28 
HAPO 
Mothers 
(GWAS) 
Pre-pregnancy Height measured, pre-pregnancy weight self reported  (Metzger et al., (2008) NEJM 358:1991-2002)30 
Fasting 
glucose 5,402 3 
EFSOCH 
Mothers 
Gestational 
week 28 
Fasting blood samples (10 hours fasting minimum) 
(Knight et al., (2006) Paediatric Perinal 
Epidemiology 20:172-179)28 
HAPO 
Mothers 
(GWAS) 
Gestational 
week 28 Fasting blood samples (Metzger et al., (2008) NEJM 
358:1991-2002)30 HAPO 
Mothers (non-
GWAS) 
Gestational 
week 28 
Gestational 
or existing 
diabetes 
6,827 1 ALSPAC Mothers 
Gestational 
week 28  
Questionnaire at recruitment about existing diabetes 
and history of gestational diabetes. Data abstracted 
on gestational diabetes and glycosuria (Lawlor et al., 
(2010) Diabetologia 53: 89-97)56 
Triglyceride
s  663 1 
EFSOCH 
Mothers 
Gestational 
week 28 
Fasting blood samples (10 hours fasting minimum) 
(Knight et al., (2006) Paediatric Perinal 
Epidemiology 20:172-179)28 
HDL 733 1 EFSOCH Mothers 
Gestational 
week 28 
Fasting blood samples (10 hours fasting minimum) 
(Knight et al., (2006) Paediatric Perinal 
Epidemiology 20:172-179)28 
Blood 
pressure  9,100 3 
ALSPAC 
Mothers 
Gestational 
week 28 
Data abstracted from obstetric medical charts at 
various time points in pregnancy. Data for 28 weeks 
gestation predicted using fractional polynomials and 
spline multilevel models. (Macdonald-Wallis et al., 
(2011) Journal of Hypertension 29: 1703-1711)57 
HAPO 
Mothers 
(GWAS) 
Gestational 
week 28 
Measured blood pressure  (Metzger et al., (2008) 
NEJM 358:1991-2002)30 
MoBa 
Mothersa 
Gestational 
week 18 
Self-reported blood pressure from medical card 
http://www.fhi.no/dokumenter/1f32a49514.pdf  
Vitamin D 
status 
(25(OH)D 
levels) 
5,305 2 
ALSPAC 
Mothers 
Gestational 
week 28 
Measured in non-fasting blood samples. Data for 28 
weeks gestation predicted using fractional 
polynomials and spline multilevel models. (Lawlor et 
al., (2013) Lancet 6736: 62203)58 
GEN-3Gb Yes (9 weeks) Measured in blood samples  
Adiponectin 1,376 1 
HAPO 
Mothers 
GWAS 
Gestational 
week 28 
Measured in fasting serum samples (Lowe et al., 
(2010) Journal Clinical Endocrinology and 
Metabolism 95: 5427-5434)59 
aBlood pressure was measured in the MoBa study and showed strong evidence of association with the genetic score (P=0.001), but since it was measured at 18 
weeks of gestation, we chose not to meta-analyse with ALSPAC and HAPO data (measured at 28 weeks). bVitamin D status was measured in the GEN-3G study 
and showed strong evidence of association the genetic score (P<5x10-5), but since it was measured at 9 weeks of gestation, we chose not to meta-analyse with 
ALSPAC data above (measured at 28 weeks).
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eTable 5. Associations between maternal genetic scores and maternal traits during and post-pregnancy in the same individuals 
 
Trait Study 
N women 
with both 
pregnancy 
and post-
pregnancy 
data 
available 
Mean (SD) 
of trait 
measured 
during 
pregnancy 
Mean (SD) 
age of 
mother when 
pregnancy 
measurement 
taken 
Change in 
maternal trait 
per trait-
increasing allele 
(95% CI) during 
pregnancy 
P value 
(during 
pregnancy) 
Mean (SD) 
of trait 
measured 
post-
pregnancy 
Mean (SD) 
age of 
mother when 
post-
pregnancy 
measurement 
taken 
Change in 
maternal trait 
per trait-
increasing allele 
(95% CI) post-
pregnancy 
P value 
(post-
pregnancy) 
BMI (kg/m2) ALSPAC 2,927 26.02 (3.55) 29.7 (4.4) 0.13 (0.09, 0.16) 7x10-14 26.54 (5.21) 48.0 (4.4) 0.14 (0.09, 0.19) 1x10-8 
BMI (kg/m2) EFSOCH 456 27.55 (4.19) 31.5 (4.7) 0.21 (0.11, 0.32) 9x10-5 25.03 (4.60) 36.8 (4.9) 0.16 (0.05, 0.28) 0.006 
Fasting glucose (mmol/L) EFSOCH 312 4.39 (0.38) 32.0 (4.4) 0.04 (0.02, 0.05) 1x10-6 4.60 (0.48) 37.1 (4.7) 0.04 (0.02, 0.06) 2x10-4 
Triglycerides (mmol/L) EFSOCH 360 2.13 (0.70) 31.6 (4.7) 0.05 (0.03, 0.08) 2x10-4 0.91 (0.40) 36.9 (4.9) 0.03 (0.01, 0.05) 4x10-4 
HDL-cholesterol (mmol/L) EFSOCH 408 2.10 (0.46) 31.5 (4.7) 0.02 (0.01, 0.03) 1x10-4 1.71 (0.42) 36.8 (4.9) 0.03 (0.02, 0.04) 7x10-9 
SBP (mmHg) ALSPAC 2,930 112.3 (7.2) 29.6 (4.5) 0.17 (0.10, 0.24) 4x10-6 117.9 (12.2) 47.9 (4.4) 0.43 (0.31, 0.56) 2x10-12 
SBP, systolic blood pressure 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. 
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(a) BMI genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 
ALSPAC, EFSOCH, HAPO (GWAS), DNBC-
GOYA-RANDOM, DNBC-PTB-CONTROLS 
[0.18] 11,822 0.145 (0.126, 0.164) 
< 2x10-16 
Waist-Hip Ratio - EFSOCH 438 0.001 (-0.001, 0.003) 0.18 
Fasting glucose mmol/L HAPO, EFSOCH [0.14] 2,104 0.005 (0.001, 0.009) 0.026 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 1.04 (0.97, 1.12) 0.28 
Triglycerides  mmol/L EFSOCH 735 0.009 (-0.006, 0.023) 0.25 
HDL-cholesterol mmol/L EFSOCH 732 -0.008 (-0.017, 0.002) 0.11 
LDL-cholesterol mmol/L EFSOCH 727 -0.004 (-0.026, 0.019) 0.76 
Systolic blood pressure mmHg ALSPAC, HAPO [0.08] 8,450 0.07 (0.02, 0.11) 0.003 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 0.002 (-0.001, 0.006) 0.25 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 -0.001 (-0.006, 0.000) 0.08 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO, EFSOCH [0.08] 9,212 1.00 (1.00, 1.01) 0.19 
Highest educational qualification attaineda   ALSPAC 6,855 -0.00 (-0.01, 0.01) 0.63 
Occupational positionb   ALSPAC 5,766 1.00 (0.99, 1.02) 0.67 
Occupational positionc   EFSOCH 612 0.015 (-0.003, 0.033) 0.11 
Townsend deprivation scored   EFSOCH 743 0.035 (-0.029, 0.100) 0.28 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
cNational Statistics Socio Economic Class Occuptation Code (3). Subjects grouped as 1=managerial & professional; 2=intermediate; 3=routine & manual 
dTownsend deprivation score, a continuous variable based on UK postal code: 0=average; >0=more deprived; <0=more affluent 
ALSPAC, Avon Longitudinal Study of Parents and Children17. DNBC-GOYA, Danish National Birth Cohort-Genetics of Obesity in Young Adults study26. DNBC-PTB-CONTROLS, Danish 
National Birth Cohort Preterm Birth study Controls27. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(b) Fasting glucose genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, EFSOCH, HAPO (GWAS) [0.89] 8,232 0.007 (-0.025, 0.039) 0.68 
Waist-Hip Ratio - EFSOCH 320 0.000 (-0.002, 0.003) 0.74 
Fasting glucose mmol/L HAPO, EFSOCH [0.70] 5,402 0.029 (0.025, 0.032) < 2x10-16 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 1.06 (0.95, 1.17) 0.29 
Triglycerides  mmol/L EFSOCH 537 -0.007 (-0.029, 0.016) 0.57 
HDL-cholesterol mmol/L EFSOCH 535 -0.004 (-0.018, 0.010) 0.57 
LDL-cholesterol mmol/L EFSOCH 531 -0.014 (-0.049, 0.022) 0.45 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.69] 8,450 0.038 (-0.026, 0.102) 0.25 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 0.003 (-0.003, 0.008) 0.34 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 -0.001 (-0.006, 0.004) 0.72 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS), EFSOCH [0.49] 9,012 0.97 (0.99, 1.00) 0.32 
Highest educational qualification attaineda   ALSPAC 6,855 -0.01 (-0.02, 0.01) 0.24 
Occupational positionb   ALSPAC 5,766 1.01 (0.98, 1.03) 0.68 
Occupational positionc   EFSOCH 447 -0.018 (-0.046, 0.011) 0.22 
Townsend deprivation scored   EFSOCH 542 -0.050 (-0.151, 0.051) 0.33 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
cNational Statistics Socio Economic Class Occuptation Code (3). Subjects grouped as 1=managerial & professional; 2=intermediate; 3=routine & manual 
dTownsend deprivation score, a continuous variable based on UK postal code: 0=average; >0=more deprived; <0=more affluent 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30 
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(c) Type 2 diabetes genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, HAPO (GWAS) [0.09] 7,901 0.010 (-0.008, 0.028) 0.28 
Waist-Hip Ratio NA         
Fasting glucose mmol/L HAPO (GWAS) 1,376 0.002 (-0.002, 0.006) 0.25 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 1.08 (1.03, 1.14) 0.003 
Triglycerides  NA - - - - 
HDL-cholesterol NA - - - - 
LDL-cholesterol NA - - - - 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.27] 8,450 0.037 (0.004, 0.071) 0.028 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 0.001 (-0.002, 0.004) 0.37 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 0.001 (-0.002, 0.003) 0.63 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS) [0.24] 8,471 1.00 (1.00, 1.00) 0.55 
Highest educational qualification attaineda   ALSPAC 6,855 -0.01 (-0.01, 0.00) 0.10 
Occupational positionb Odds ratio ALSPAC 5,766 1.00 (0.99, 1.01) 0.95 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
ALSPAC, Avon Longitudinal Study of Parents and Children17. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30 
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(d) Triglycerides genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, EFSOCH, HAPO (GWAS) [0.06] 8,353 -0.007 (-0.041, 0.027) 0.70 
Waist-Hip Ratio - EFSOCH 392 0.000 (-0.002, 0.003) 0.84 
Fasting glucose mmol/L HAPO (GWAS), EFSOCH [0.07] 2,036 0.002 (-0.003, 0.008) 0.42 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 0.93 (0.83, 1.04) 0.19 
Triglycerides  mmol/L EFSOCH 663 0.055 (0.032, 0.078) 3x10-6 
HDL-cholesterol mmol/L EFSOCH 660 -0.003 (-0.018, 0.012) 0.71 
LDL-cholesterol mmol/L EFSOCH 656 0.003 (-0.033, 0.039) 0.88 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.97] 8,450 0.002 (-0.065, 0.069) 0.96 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 0.003 (-0.003, 0.009) 0.27 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 0.000 (-0.004, 0.004) 0.93 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS), EFSOCH [0.23] 9,142 1.00 (0.99, 1.01) 0.87 
Highest educational qualification attaineda   ALSPAC 6,855 0.00 (-0.01, 0.01) 0.78 
Occupational positionb Odds ratio ALSPAC 5,766 1.01 (0.98, 1.04) 0.47 
Occupational positionc   EFSOCH 556 -0.004 (-0.034, 0.026) 0.81 
Townsend deprivation scored   EFSOCH 671 0.009 (-0.097, 0.115) 0.87 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
cNational Statistics Socio Economic Class Occuptation Code (3). Subjects grouped as 1=managerial & professional; 2=intermediate; 3=routine & manual 
dTownsend deprivation score, a continuous variable based on UK postal code: 0=average; >0=more deprived; <0=more affluent 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(e) HDL-cholesterol genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, EFSOCH, HAPO (GWAS) [0.10] 8,420 -0.048 (-0.097, 0.002) 0.06 
Waist-Hip Ratio - EFSOCH 438 0.002 (-0.002, 0.005) 0.40 
Fasting glucose mmol/L HAPO (GWAS), EFSOCH [0.48] 2,107 -0.002 (-0.011, 0.007) 0.70 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 0.83 (0.70, 0.99) 0.04 
Triglycerides  mmol/L EFSOCH 736 0.001 (-0.035, 0.037) 0.96 
HDL-cholesterol mmol/L EFSOCH 733 0.050 (0.027, 0.072) 1x10-5 
LDL-cholesterol mmol/L EFSOCH 728 -0.032 (-0.088, 0.024) 0.26 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.77] 8,450 -0.013 (-0.112, 0.085) 0.79 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 -0.000 (-0.009, 0.008) 0.95 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 -0.001 (-0.007, 0.005) 0.81 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS), EFSOCH [0.38] 9,215 1.00 (0.99, 1.00) 0.29 
Highest educational qualification attaineda   ALSPAC 6,855 0.01 (-0.01, 0.02) 0.55 
Occupational positionb   ALSPAC 5,766 1.00 (0.96, 1.04) 0.93 
Occupational positionc   EFSOCH 613 0.004 (-0.042, 0.049) 0.87 
Townsend deprivation scored   EFSOCH 744 0.081 (-0.081, 0.243) 0.33 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
cNational Statistics Socio Economic Class Occuptation Code (3). Subjects grouped as 1=managerial & professional; 2=intermediate; 3=routine & manual 
dTownsend deprivation score, a continuous variable based on UK postal code: 0=average; >0=more deprived; <0=more affluent 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(f) Systolic blood pressure genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, HAPO (GWAS) [0.78] 7,741 -0.011 (-0.030, 0.008) 0.27 
Waist-Hip Ratio NA         
Fasting glucose mmol/L HAPO (GWAS) 1,376 0.002 (-0.003, 0.007) 0.45 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 0.98 (0.91, 1.05) 0.52 
Triglycerides  NA - - - - 
HDL-cholesterol NA - - - - 
LDL-cholesterol NA - - - - 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.04] 8,450 0.186 (0.140, 0.231) < 2x10-16 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 -0.001 (-0.005, 0.002) 0.45 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,376 0.001 (-0.002, 0.004) 0.46 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS) [0.36] 8,471 1.00 (0.99, 1.00) 0.17 
Highest educational qualification attaineda   ALSPAC 6,855 0.00 (-0.00, 0.01) 0.32 
Occupational positionb   ALSPAC 5,766 0.99 (0.97, 1.01) 0.43 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
ALSPAC, Avon Longitudinal Study of Parents and Children17. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(g) Vitamin D genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, EFSOCH, HAPO (GWAS) [0.86] 8,420 0.073 (-0.019, 0.164) 0.12 
Waist-Hip Ratio - EFSOCH 438 -0.001 (-0.008, 0.005) 0.68 
Fasting glucose mmol/L HAPO (GWAS), EFSOCH [0.96] 2,109 -0.001 (-0.019, 0.016) 0.96 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 1.19 (0.88, 1.62) 0.25 
Triglycerides  mmol/L EFSOCH 736 0.001 (-0.060, 0.061) 0.98 
HDL-cholesterol mmol/L EFSOCH 733 -0.034 (-0.072, 0.005) 0.09 
LDL-cholesterol mmol/L EFSOCH 728 0.048 (-0.046, 0.141) 0.32 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.98] 8,454 -0.030 (-0.211, 0.151) 0.98 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 0.024 (0.009, 0.039) 0.002 
Adiponectin log10(ug/ml) HAPO (GWAS) 1,339 -0.029 (-0.772, 0.713) 0.94 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS), EFSOCH [0.83] 9,217 1.00 (0.95, 1.05) 0.98 
Highest educational qualification attaineda   ALSPAC 6,855 0.033 (0.001, 0.065) 0.05 
Occupational positionb Odds ratio ALSPAC 5,766 0.95 (0.88, 1.02) 0.17 
Occupational positionc   EFSOCH 613 0.057 (-0.017, 0.130) 0.13 
Townsend deprivation scored   EFSOCH 744 -0.058 (-0.329, 0.213) 0.67 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
cNational Statistics Socio Economic Class Occuptation Code (3). Subjects grouped as 1=managerial & professional; 2=intermediate; 3=routine & manual 
dTownsend deprivation score, a continuous variable based on UK postal code: 0=average; >0=more deprived; <0=more affluent 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30
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eTable 6. Associations between each maternal genetic score and potentially confounding or mediating variables 
(h) Adiponectin genetic score 
Outcome variable tested for association (measured 
or ascertained during pregnancy, except BMI and 
WHR) 
Units of 
outcome 
variable 
Study(ies) [Phet from meta-analysis] Total N women 
Estimated change in 
outcome variable per 
trait-raising allele 
(95%CI) 
P-value 
Body Mass Index kg/m2 ALSPAC, HAPO (GWAS) [0.79] 7,741 -0.04 (-0.23, 0.14) 0.61 
Waist-Hip Ratio NA - - - - 
Fasting glucose mmol/L HAPO 1,376 -0.01 (-0.06, 0.04) 0.69 
Gestational/existing diabetes Odds ratio ALSPAC 6,827 1.57 (0.94, 2.64) 0.09 
Triglycerides  NA - - - - 
HDL-cholesterol NA - - - - 
LDL-cholesterol NA - - - - 
Systolic blood pressure mmHg ALSPAC, HAPO (GWAS) [0.66] 8,450 -0.047 (-0.389, 0.295) 0.79 
Vitamin D, ln[25(OH)D]   ALSPAC 4,767 -0.015 (-0.043, 0.012) 0.28 
Adiponectin ln(ug/ml) HAPO (GWAS) 1,376 0.17 (0.11, 0.23) 1x10-8 
Smoking (current smoker vs non-smoker) Odds ratio ALSPAC, HAPO (GWAS) [0.91] 8,471 0.97 (0.93, 1.02) 0.22 
Highest educational qualification attaineda NA ALSPAC 6,855 -0.04 (-0.10, 0.02) 0.16 
Occupational positionb Odds ratio ALSPAC 5,766 0.96 (0.84, 1.10) 0.57 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
ALSPAC, Avon Longitudinal Study of Parents and Children17. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30.
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eTable 7. Associations between maternal genetic scores and ponderal index of offspring at birth 
Maternal exposure 
for which genetic  
score was 
constructed 
N 
Studies 
Total 
N 
women 
Change in 
ponderal index z-
score per 
additional 
maternal trait 
raising/lowering 
allele  (95% CI)a 
Equivalent 
change in 
PI (kgm-3) 
per allele 
(95% CI)b 
P 
value 
Heterogeneity 
P Value; I2 % 
from meta-
analysis 
N 
Studies 
with 
fetal 
genotype 
Total N 
offspring 
with 
genotype 
data 
Change in PI 
z-score per 
additional 
maternal 
trait raising 
/loweringa 
allele  (95% 
CI)c 
Equivalent 
change in 
PI (kgm-3) 
per allele 
(95% CI)b 
P 
value 
Heterogeneity 
P Value (I2 
%) from 
meta-analysis 
Higher pre-
pregnancy BMI 10 17,743 
0.006 (0.002, 
0.010) 
0.02 (0.01, 
0.03) 0.003 0.48; 0 7 9,628 
0.006 (0.000, 
0.012) 
0.02 (0.00, 
0.03) 0.05 0.38; 6.5 
Higher fasting 
glucose 10 17,818 
0.007 (0.001, 
0.012) 
0.02 (0.00, 
0.03) 0.02 0.49; 0 8 9,902 
0.014 (0.005, 
0.022) 
0.04 (0.01, 
0.06) 0.001 0.78; 0 
Higher odds of type 
2 Diabetes 7 13,518 
0.002 (-0.002, 
0.005) 
0.01 (-0.01, 
0.01) 0.3 0.20; 29.6 5 6,800 
0.005 (0.000, 
0.011) 
0.01 (0.00, 
0.03) 0.05 0.11; 47.5 
Higher odds of type 
2 Diabetes 
(excluding pre-
existing and 
gestational 
diabetes) 
6 11,653 0.002 (-0.001, 0.006) 
0.01 (0.00, 
0.02) 0.18 0.32; 14.9 4 5,330 
0.008 (0.002, 
0.014) 
0.02 (0.01, 
0.04) 0.01 0.38; 2.9 
Higher triglycerides 9 17,440 0.000 (-0.006, 0.007) 
0.00 (-0.02, 
0.02) 0.89 0.11; 39.0 6 9,335 
-0.004 (-
0.014, 0.005) 
-0.01 (-0.04, 
0.01) 0.41 0.07; 51.3 
Lower HDL-
cholesterol 9 15,573 
0.005 (-0.004, 
0.014) 
0.01 (-0.01, 
0.04) 0.27 0.45; 0 6 8,207 
-0.001 (-
0.013, 0.012) 
0.00 (-0.04, 
0.03) 0.92 0.13; 41.4 
Higher systolic 
blood pressure 7 13,527 
-0.005 (-0.010, -
0.001) 
-0.01 (-0.03. 
0.00) 0.03 0.74; 0 5 6,821 
-0.003 (-
0.011, 0.004) 
-0.01 (-0.03, 
0.01) 0.43 0.14; 42.3 
Higher systolic 
blood pressure 
(excluding pre-
eclampsia and 
hypertension) 
6 10,770 -0.005 (-0.010, 0.000) 
-0.01 (-0.03, 
0.00) 0.07 0.60; 0 4 4,735 
-0.005 (-
0.014, 0.004) 
-0.01 (-0.04, 
0.01) 0.25 0.28; 22.2 
Lower vitamin D 
status 7 14,004 
-0.007 (-0.025, 
0.011) 
-0.02 (-0.07, 
0.03) 0.44 0.22; 27.9 3 7,292 
-0.026 (-
0.054, 0.002) 
-0.07 (-0.15, 
0.01) 0.07 0.04; 68.7 
Lower adiponectin 6 11,501 0.017 (-0.020, 0.054) 
0.05 (-0.06, 
0.15) 0.37 0.83; 0 5 6,851 
0.039 (-0.016, 
0.094) 
0.11 (-0.04, 
0.26) 0.17 0.89; 0 
aThe decision to model the association in relation to the trait-raising or trait-lowering allele depended on the known direction of association of each trait with higher BMI (see Box 1). Column 
1 specifies each of these directions of association. Results are per average weighted allele, adjusted for sex and gestational age. bStandard deviation of ponderal index from ALSPAC study was 
used for these estimates (=2.78 kg/m3). cResults are per average weighted allele, adjusted for sex, gestational age and fetal genotype
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eTable 8. A comparison of the observational with the genetic association between each maternal trait and offspring ponderal index at birth 
Maternal trait 
(value of 1 SD 
with units) 
Value of a 1 
SD change in 
the trait with 
units 
Study/iesa used for 
observational estimates 
[Total N women] 
N women 
Observational 
estimate of the 
change in 
ponderal index 
(kg/m3) per 1 SD 
(or 10% b) 
change in 
maternal trait, 
adjusted for sex 
and gestational 
age (95%CI) 
Genetic estimate 
of the change in 
ponderal index 
(kg/m3), adjusted 
for sex and 
gestational age, 
per 1 SD (or 10% 
b) change in 
maternal trait, 
unadjusted for 
fetal genotype 
(95%CI)  
 P value c 
comparing 
observational 
with genetic 
ponderal index 
associations 
(unadjusted for 
fetal genotype) 
Genetic estimate of 
the change in 
ponderal index 
(kg/m3), adjusted for 
sex, gestational age 
and fetal genotype, 
per 1 SD (or 10% b) 
change in maternal 
trait (95%CI)  
 P value c 
comparing 
observational 
with genetic 
ponderal index 
associations 
(adjusted for 
fetal genotype) 
Higher pre-
pregnancy BMI  4 kg/m
2 
ALSPAC Mothers, 
EFSOCH Mothers, 
HAPO Mothers 
9,690 0.24 (0.19, 0.29) 0.45 (0.14, 0.75) 0.20 0.47 (0.14, 0.79) 0.21 
Higher fasting 
glucose  0.4 mmol/L 
EFSOCH Mothers, 
HAPO Mothers 4,917 0.31 (0.22, 0.39) 0.27 (0.05, 0.48) 0.72 0.53 (0.20, 0.87) 0.24 
Higher 
triglycerides  0.7 mmol/L EFSOCH Mothers 857 0.15 (-0.03, 0.33) 0.02 (-0.21, 0.24) 0.35 -0.14 (-0.48, 0.20) 0.14 
Lower HDL-
cholesterol 0.5 mmol/L EFSOCH Mothers 854 0.12 (-0.08, 0.31) 0.14 (-0.11, 0.39) 0.91 -0.02 (-0.37, 0.34) 0.51 
Higher Systolic 
blood pressure  10 mmHg 
ALSPAC Mothers, 
HAPO Mothers 9,691 0.00 (-0.08, 0.06) -0.77 (-1.80, 0.25) 0.16 -0.46 (-1.95, 1.03) 0.56 
Lower vitamin D 
status 10% 
b ALSPAC Mothers 3,718 -0.02 (-0.03, 0.00) -0.08 (-0.28, 0.13) 0.56 -0.29 (-0.65, 0.07) 0.14 
Lower adiponectin 10% b HAPO Mothers (GWAS only) 1,373 0.05 (0.02, 0.08) 0.03 (-0.03, 0.09) 0.49 0.06 (-0.03, 0.15) 0.82 
aHeterogeneity statistics from the meta-analyses of observational associations were: Phet = 0.35 and I2 = 9.1%  for BMI; Phet = 0.23 and I2 =32.7%  for fasting glucose; Phet = 0.67 and I2 = 
0%  for SBP.  
bFor 25[OH]D and adiponectin, we present the estimated change in ponderal index per 10% reduction in maternal trait level because these variables were logged for analysis. 
cP-values <0.05 are considered to indicate evidence that the genetic effect size estimate is different from the observational estimate, suggesting that the observational estimate is subject to 
confounding or bias. 
ALSPAC, Avon Longitudinal Study of Parents and Children17. EFSOCH, Exeter Family Study Of Childhood Health28. HAPO, Hyperglycemia and Adverse Pregnancy Outcome study30.
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eTable 9 
 
(a) Observational associations between offspring birth weight and maternal socio-economic status or 
maternal smoking in the ALSPAC study17 
Maternal trait N women 
Change in birth 
weight (g) per unit 
change in maternal 
trait (95% CI) 
P 
Highest educational qualification attaineda 6,855 19 (10, 29) 0.00004 
Occupational positionb 5,588 -34 (-68, 0) 0.06 
Smoking (current smoker vs non-smoker) 7,021 -208 (-237, -179) 1x10-43 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects 
dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
 
 
 
(b) Observational associations between maternal BMI and maternal socio-economic status or maternal 
smoking in the ALSPAC study17 
 
Maternal trait N women 
Change in BMI (kgm-2) 
per unit change in 
maternal trait (95%CI) 
P 
Highest educational qualification attaineda 6,115 -0.35 (-0.42, -0.27) 9x10-20 
Occupational positionb 5,128 0.38 (0.11, 0.65) 0.005 
Smoking (current smoker vs non-smoker) 6,238 0.01 (-0.24, 0.26) 0.95 
aSubjects grouped as: 1=CSE; 2=Vocational; 3=Ordinary Level; 4=Advanced level; 5=Degree 
bDerived from Office of Population Censuses & Surveys Standard Occupational Classification (1). Subjects 
dichotomized as: 0=I, II & III (non-manual); 1=III (manual), IV & V. 
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eTable 10. Power calculations 
 
Maternal trait Total 
N 
women 
Adjusted-
R2 from 
BW~GA 
sex 
Adjusted-
R2 from 
BW~GA 
sex GS 
Estimated 
proportion of 
variance in 
birth weight 
explained by 
maternal 
genetic score 
Power available in 
our included sample 
to detect evidence of 
association between 
maternal genetic 
score and birth 
weight at P<0.05 
Minimum sample 
size needed to detect 
association between 
maternal genetic 
score and birth 
weight at P<0.05 
with 80% power 
BMI 25265 0.1308 0.1312 0.0004 0.89 19618 
Fasting glucose 23902 0.1308 0.1319 0.0011 1.00 7131 
Type 2 diabetes 18670 0.1308 0.1312 0.0004 0.78 19618 
Triglycerides 24985 0.1308 0.1307 -0.0001* 0.35 78485 
HDL-
cholesterol 
22167 0.1308 0.1307 -0.0001* 0.32 78485 
Systolic Blood 
Pressure 
20062 0.1308 0.1324 0.0016 1.00 4902 
25-hydroxy 
vitamin D 
30340 0.1308 0.1309 0.0001 0.41 78485 
Adiponectin 14920 0.1308 0.1307 -0.0001* 0.23 78485 
*Where the estimated variance explained was negative, we assumed a value of 0.0001 for the 
calculations. BW, birth weight; GA, gestational age; GS, genetic score.
49	
	
eTable 11. Association between father’s phenotypes and offspring birth weight using data from the ALSPAC study17  
Father’s phenotype N men 
Correlation coefficient (95% CI) 
of father’s phenotype with 
offspring birth weight 
BMI* 7491 0.04 (0.02, 0.06) 
BMI 1721 0.03 (-0.02, 0.07) 
Systolic BP 1732 -0.03 (-0.07, 0.01) 
Glucose 1656 -0.01 (-0.06, 0.03) 
Triglycerides 1656 -0.02 (-0.07, 0.02) 
HDLc 1656 0.02 (-0.03, 0.06) 
* Based on paternal report of weight and height at the time that their partner was in early pregnancy; all other phenotypes were assessed at a clinic visit ~18-19 years after the child’s birth. 
Correlation coefficients of paternal phenotypes with offspring birth weight were all weak and mostly null (Pearson correlation coefficients all ≤ 0.04).  
The correlation between and offspring birth weight and father’s BMI, assessed when the mothers were pregnant, was similar to that between offspring birth weight and father’s BMI 18 years 
later, suggesting that the postnatal measures for other phenotypes are a reasonable approximation for them before/at the time of their partner’s pregnancy.
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